Champions Oncology (CSBR)
(Delayed Data from NSDQ)
$6.57 USD
-0.14 (-2.01%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.61 +0.05 (0.69%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CSBR 6.57 -0.14(-2.01%)
Will CSBR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CSBR based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CSBR
Is CSBR about to break its pattern? Calm After Storm shows up after declining 2.01%
CSBR forms MACD Bearish Signal Line Cross on September 19
20 Day Moving Average Resistance appears for CSBR after 8.9% move
Fell Below 20 Day Moving Average appears for CSBR after 16.02% move
Champions Oncology Earnings Call: Cautious Optimism Amid Challenges